Stocktoria

Ocugen, Inc. OCGN

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2014-12-03 · LEI

Ocugen, Inc. financials (annual)

Revenue
$0 $0 $0 $0 $43000 $0 $2.5M $6.0M $4.1M $4.4M 2016201720182019202020212022202320242025
Net income
-$16.2M -$26.4M -$18.2M -$20.2M -$21.8M -$58.4M -$86.8M -$63.1M -$54.1M -$67.8M 2016201720182019202020212022202320242025
Free cash flow
-$26.1M -$23.3M -$11.7M -$16.9M -$15.0M -$48.9M -$64.5M -$72.5M -$45.5M -$57.1M 2016201720182019202020212022202320242025

Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$4.4M$4.1M$6.0M$2.5M$0$43,000$0$0$0$0
R&D expense$39.8M$32.1M$39.6M$8.1M$10.3M$15.6M$21.6M
Operating income-$62.9M-$54.8M-$65.5M-$89.1M-$58.0M-$21.3M-$14.2M-$16.1M-$24.9M-$30.3M
Interest expense$79,000$721,000$1.8M$3.8M$60,000
Income tax$0$0$0$0-$52,000$0$0
Net income-$67.8M-$54.1M-$63.1M-$86.8M-$58.4M-$21.8M-$20.2M-$18.2M-$26.4M-$16.2M
EPS (diluted)$-0.26$-0.40$-0.30$-0.31$-1.46$-0.79$-0.99$-2.18
Operating cash flow-$57.0M-$42.1M-$62.1M-$60.1M-$47.9M-$14.7M-$16.9M-$11.6M-$23.0M-$25.7M
Free cash flow-$57.1M-$45.5M-$72.5M-$64.5M-$48.9M-$15.0M-$16.9M-$11.7M-$23.3M-$26.1M
Cash & equivalents$18.6M$39.5M$77.6M$95.0M$24.0M$7.4M$1.6M$7.1M$31.9M
Total assets$43.5M$82.4M$64.5M$108.6M$105.8M$27.4M$16.8M$2.5M$11.0M$36.1M
Total liabilities$55.7M$52.8M$24.0M$34.7M$9.9M$5.8M$5.8M$15.2M$22.3M$22.5M
Shareholders' equity-$12.2M$29.6M$40.6M$74.0M$91.2M$21.6M$11.0M-$12.7M$4.4M$13.6M

Growth · year-over-year

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue growth+8.8%-32.8%+142.6%-100.0%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.